Co-tenidone

Co-tenidone
Combination of
Atenolol	Beta blocker
Chlortalidone	Thiazide diuretic
Clinical data
Legal status	UK: POM (Prescription only)
Routes of administration	Oral
Identifiers
ChemSpider	151231^Y
(verify)

Co-tenidone (BAN) is a non-proprietary name used to denote a combination of atenolol and chlortalidone. Co-tenidone is used in the treatment of hypertension. The use of β-blockers in hypertension was downgraded in June 2006 in the United Kingdom to fourth-line because they perform less well than other drugs, and because atenolol, the most frequently used β-blocker, at usual doses carries an unacceptable risk of provoking type 2 diabetes.^[1]

Formulation

Two strengths of co-tenidone are currently available in the UK:

50 mg atenolol and 12.5 mg chlortalidone, BAN of Co-tenidone 50/12.5
100 mg atenolol and 25 mg chlortalidone, BAN of Co-tenidone 100/25

References

British National Formulary 54 September 2007

Footnotes

↑ Sheetal Ladva (2006-06-28). "NICE and BHS launch updated hypertension guideline". National Institute for Health and Clinical Excellence.

Sympatholytic (and closely related) antihypertensives (C02)

Sympatholytics
(antagonize α-adrenergic
vasoconstriction)

Central

α₂ agonist	Clonidine Guanabenz Guanfacine Methyldopa^# Tiamenidine^‡

Adrenergic release inhibitors	Bethanidine Bretylium Debrisoquine Guanadrel Guanazodine Guanethidine Guanoclor Guanazodine Guanoxabenz Guanoxan

Imidazoline receptor agonist	Moxonidine Rilmenidine

Ganglion-blocking/nicotinic antagonist	Hexamethonium^‡ Mecamylamine Pentolinium Trimethaphan

Peripheral

Indirect

MAOI	Pargyline^‡

Adrenergic uptake inhibitor	Bietaserpine Deserpidine Methoserpidine Rescinnamine Reserpine

Tyrosine hydroxylase inhibitor	Metirosine

Direct

α₁ blockers	Prazosin Indoramin Trimazosin Doxazosin Urapidil

Non-selective α blocker	Phentolamine

Other antagonists

Serotonin antagonist	Ketanserin Lidanserin

Endothelin antagonist (for PH)	dual (Bosentan, Macitentan) selective (Ambrisentan, Sitaxentan)

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Monday, August 11, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.